
  
    
      
        
        In_IN 1996_CD ,_, Richard_NNP Horton_NNP ,_, editor_NN of_IN the_DT 
        Lancet_NNP ,_, chastised_VBD much_RB of_IN current_JJ surgical_JJ research_NN and_CC ,_, in_IN particular_NN ,_,
        questioned_VBD the_DT usefulness_NN of_IN the_DT case_NN series_NN as_IN a_DT predominant_NN form_NN of_IN communication_NN among_IN
        surgeons_NNS [_NN 1_CD ]_NN ._. He_PRP asked_VBD a_DT poignant_JJ question_NN :_: “ Does_VBZ surgical_JJ research_NN have_VBP a_DT future_NN ?_.” Nearly_RB
        a_DT decade_NN later_RB ,_, it_PRP is_VBZ important_JJ for_IN surgeons_NNS and_CC non-surgeons_JJ alike_RB to_TO revisit_VB Horton_NNP 's_POS
        challenge_NN ._.
      
      
        Why_WRB Surgeons_NNP Favor_NNP Case_NNP Series_NNP
        Randomized_NNP controlled_VBD trials_NNS (_( RCTs_NNP )_) have_VBP become_VBN the_DT pillar_NN of_IN clinical_JJ research_NN ._. Such_JJ
        trials_NNS attempt_VBP to_TO obtain_VB an_DT unbiased_JJ randomization_NN of_IN patients_NNS with_IN respect_NN to_TO known_VBN and_CC
        unknown_JJ baseline_NN conditions_NNS and_CC to_TO assess_VB the_DT effects_NNS of_IN an_DT intervention_NN ._. However_RB ,_, only_RB a_DT
        minority_NN of_IN surgical_JJ studies_NNS involve_VBP a_DT valid_JJ randomization_NN scheme_NN ._. The_DT case_NN series_NN remains_VBZ
        a_DT favored_VBN method_NN of_IN clinical_JJ investigation_NN in_IN surgery_NN ._.
        Case_NN series_NN are_VBP easy_JJ to_TO perform_VB ,_, require_VB less_JJR resources_NNS in_IN terms_NNS of_IN personnel_NNS and_CC funds_NNS ,_,
        can_MD be_VB performed_VBN at_IN a_DT single_JJ center_NN ,_, and_CC ,_, for_IN many_JJ surgeons_NNS ,_, represent_VBP a_DT means_NN to_TO
        illustrate_VB their_PRP$ surgical_JJ method_NN and_CC skills_NNS ._. In_IN many_JJ instances_NNS ,_, case_NN series_NN also_RB serve_VB as_IN
        valuable_JJ intellectual_JJ background_NN for_IN future_JJ clinical_JJ or_CC scientific_JJ work_NN ._. For_IN example_NN ,_,
        consider_VB Dennis_NNP Burkitt_NNP 's_POS report_NN on_IN jaw_NN tumors_NNS in_IN African_JJ children_NNS ,_, Alfred_NNP Blalock_NNP 's_POS
        initial_JJ efforts_NNS in_IN cardiac_JJ surgery_NN ,_, or_CC ,_, more_RBR recently_RB ,_, Starzl_NNP and_CC colleagues_NNS '_POS observations_NNS ,_,
        in_IN a_DT small_JJ collection_NN of_IN patients_NNS ,_, of_IN donor_NN leukocyte_NN chimerism_NN ,_, whereby_WRB recipients_NNS acquire_VB
        tolerance_NN to_TO foreign_JJ donor_NN cells_NNS ._. In_IN all_DT three_CD cases_NNS ,_, the_DT authors_NNS '_POS work_NN led_VBD to_TO powerful_JJ
        shifts_NNS in_IN our_PRP$ understanding_NN of_IN the_DT biology_NN and_CC treatment_NN of_IN disease_NN [_NN 2_CD ,_, 3_CD ,_, 4_CD ]_NN ._. All_DT were_VBD case_NN
        reports_NNS or_CC case_NN series—but_NN under_IN the_DT current_JJ paradigm_NN adopted_VBN by_IN most_JJS journals_NNS and_CC
        evidence-based_JJ databases_NNS ,_, they_PRP would_MD not_RB be_VB valued_VBN [_NN 5_CD ,_, 6_CD ,_, 7_CD ]_NN ._.
      
      
        Barriers_NNP to_TO Surgical_NNP RCTs_NNP
        There_EX are_VBP many_JJ reasons_NNS why_WRB RCTs_NNP in_IN surgical_JJ patients_NNS may_MD be_VB more_RBR difficult_JJ to_TO perform_VB
        than_IN those_DT in_IN non-surgical_JJ patients_NNS ._. One_CD of_IN the_DT most_JJS important—though_NN least_JJS understood—is_NNS
        that_IN the_DT complexities_NNS of_IN human_JJ disease_NN in_IN surgical_JJ patients_NNS makes_VBZ them_PRP a_DT more_RBR difficult_JJ
        group_NN to_TO study_VB ._. Surgical_NNP patients_NNS are_VBP often_RB heterogeneous_JJ in_IN many_JJ more_JJR ways_NNS than_IN
        non-surgical_JJ patients_NNS ._. So_IN it_PRP would_MD be_VB inherently_RB easier_JJR ,_, for_IN example_NN ,_, to_TO study_VB a_DT new_JJ
        medication_NN for_IN generally_RB healthy_JJ young_JJ adults_NNS with_IN essential_JJ hypertension_NN than_IN a_DT surgical_JJ
        technique_NN for_IN older_JJR patients_NNS with_IN hepatic_JJ failure_NN needing_VBG transplantation_NN ._.
        In_IN addition_NN ,_, while_IN there_EX may_MD be_VB value_NN in_IN studying_VBG patients_NNS from_IN multiple_JJ centers_NNS ,_, there_EX
        may_MD be_VB important_JJ differences_NNS in_IN the_DT skill_NN levels_NNS of_IN different_JJ surgeons_NNS ,_, either_CC between_IN
        centers_NNS or_CC across_IN the_DT country_NN ._. For_IN example_NN ,_, the_DT skill_NN levels_NNS of_IN surgeons_NNS in_IN trials_NNS of_IN
        carotid_NN endarterectomy_NN may_MD be_VB greater_JJR than_IN those_DT across_IN the_DT surgical_JJ community_NN as_IN a_DT whole_NN ._.
        This_DT makes_VBZ the_DT applicability_NN of_IN some_DT surgical_JJ RCTs_NNP to_TO the_DT wider_JJR community_NN less_RBR certain_JJ than_IN
        trials_NNS of_IN medical_JJ therapies_NNS ._.
        So_RB when_WRB it_PRP comes_VBZ to_TO surgical_JJ research_NN ,_, for_IN both_DT researchers_NNS and_CC funding_NN agencies_NNS ,_, it_PRP is_VBZ
        easier_JJR to_TO grapple_VB with_IN a_DT difficult_JJ ,_, but_CC ultimately_RB soluble_JJ ,_, basic_JJ science_NN question_NN than_IN to_TO
        face_VB the_DT uncertainty_NN of_IN clinical_JJ research_NN ._. Investigators_NNS understand_VBP these_DT implicit_JJ issues_NNS
        and_CC trim_VB their_PRP$ sails_NNS accordingly_RB ._.
      
      
        Improving_VBG the_DT Rigor_NNP of_IN Research_NNP
        Nonetheless_RB ,_, too_RB much_JJ surgical_JJ work_NN is_VBZ conducted_VBN in_IN the_DT less_RBR rigorous_JJ format_NN of_IN the_DT case_NN
        series_NN ._. What_WP can_MD and_CC should_MD be_VB done_VBN to_TO improve_VB the_DT rigor_NN of_IN surgical_JJ investigation_NN ?_. It_PRP
        would_MD seem_VB that_IN improvements_NNS are_VBP required_VBN from_IN within_IN and_CC beyond_IN the_DT surgical_JJ world_NN ._.
        First_LS ,_, as_IN Horner_NNP observed_VBD ,_, and_CC several_JJ eminent_JJ surgeons_NNS have_VBP since_IN agreed_VBN ,_, reforms_NNS must_MD
        begin_VB within_IN the_DT field_NN itself_PRP [_NN 1_CD ,_, 5_CD ,_, 6_CD ,_, 7_CD ]_NN ._. Both_DT during_IN surgical_JJ training_NN and_CC in_IN the_DT early_JJ
        years_NNS of_IN faculty_NN development_NN ,_, surgeons_NNS must_MD obtain_VB a_DT thorough_JJ grounding_NN in_IN the_DT principles_NNS
        of_IN basic_JJ research_NN and_CC proper_JJ clinical_JJ investigation_NN ._.
        Second_JJ ,_, surgeons_NNS must_MD establish_VB firm_NN and_CC friendly_JJ relations_NNS with_IN biostatisticians_NNS so_IN
        that_IN the_DT latter_NN may_MD play_VB a_DT strong_JJ role_NN in_IN helping_VBG to_TO develop_VB adequately_RB powered_VBN studies_NNS
        that_WDT can_MD answer_VB critical_JJ questions_NNS raised_VBN by_IN new_JJ therapies_NNS and_CC techniques_NNS ._. This_DT is_VBZ an_DT
        especially_RB acute_JJ need_NN in_IN an_DT accelerating_VBG age_NN of_IN targeted_VBN therapies_NNS and_CC disease_NN
        biomarkers_NNS ._.
        Third_NNP ,_, surgeons_NNS must_MD re-engage_JJ in_IN the_DT clinical_JJ research_NN enterprise_NN and_CC resume_VB leadership_NN
        roles_NNS in_IN local_JJ and_CC national_JJ clinical_JJ trials_NNS that_WDT involve_VBP surgical_JJ patients_NNS ._. In_IN the_DT United_NNP
        States_NNPS ,_, for_IN example_NN ,_, an_DT important_JJ step_NN in_IN this_DT regard_NN has_VBZ been_VBN the_DT establishment_NN of_IN the_DT
        American_NNP College_NNP of_IN Surgeons_NNP Oncology_NNP Group_NNP ,_, which_WDT invites_VBZ surgeons_NNS from_IN all_DT sectors_NNS ,_,
        including_VBG private_JJ practice_NN ,_, to_TO become_VB active_JJ participants_NNS in_IN well-designed_JJ ,_,
        multi-institutional_JJ trials_NNS [_NN 5_CD ]_NN ._. Similar_JJ efforts_NNS are_VBP needed_VBN on_IN a_DT global_JJ level_NN ._.
        Finally_RB ,_, similar_JJ to_TO the_DT pressures_NNS faced_VBN by_IN their_PRP$ colleagues_NNS elsewhere_RB in_IN academia_NN ,_,
        surgeon_NN clinician-investigators_JJ must_MD be_VB nurtured_VBN ,_, protected_VBN ,_, and_CC valued_VBN by_IN their_PRP$ colleagues_NNS
        and_CC medical_JJ administrators_NNS ._. The_DT financial_JJ health_NN of_IN academic_JJ medical_JJ centers_NNS relies_VBZ heavily_RB
        on_IN the_DT generation_NN of_IN clinical_JJ revenue_NN ,_, which_WDT in_IN many_JJ centers_NNS falls_VBZ disproportionately_RB on_IN
        the_DT shoulders_NNS of_IN surgeons_NNS ._. New_JJ paradigms_NNS for_IN revenue_NN generation_NN and_CC funding_NN of_IN clinical_JJ
        research_NN are_VBP needed_VBN ._.
      
      
        Funding_NNP for_IN Surgical_NNP Research_NNP
        Beyond_IN the_DT walls_NNS of_IN the_DT academic_JJ medical_JJ center_NN ,_, there_EX also_RB needs_VBZ to_TO be_VB greater_JJR
        recognition_NN of_IN the_DT value_NN of_IN scientifically_RB sound_NN surgical_JJ research_NN and_CC clinical_JJ
        investigation_NN ._. However_RB ,_, the_DT National_NNP Institutes_NNPS of_IN Health_NNP (_( NIH_NNP )_) ,_, the_DT major_JJ source_NN of_IN
        biomedical_JJ funding_NN in_IN the_DT United_NNP States_NNPS ,_, continues_VBZ to_TO convey_VB a_DT less_JJR welcoming_VBG attitude_NN
        toward_IN surgical_JJ research_NN than_IN toward_IN other_JJ types_NNS of_IN clinical_JJ or_CC basic_JJ science_NN [_NN 8_CD ,_, 9_CD ]_NN ._.
        At_IN the_DT NIH_NNP ,_, the_DT principal_JJ instrument_NN for_IN performing_VBG peer_VBP review_NN and_CC making_VBG grant_NN funding_NN
        decisions_NNS is_VBZ the_DT study_NN section_NN ,_, composed_VBN of_IN about_IN 10_CD –_NN 20_CD members_NNS with_IN expertise_NN in_IN a_DT given_VBN
        field_NN ._. There_EX are_VBP few_JJ study_NN sections_NNS devoted_VBN to_TO surgically_RB oriented_VBN clinical_JJ research_NN and_CC
        only_RB two_CD study_NN sections_NNS (_( from_IN among_IN more_JJR than_IN 100_CD )_) in_IN which_WDT surgeons_NNS make_VBP up_RB even_RB a_DT
        reasonable_JJ minority_NN of_IN the_DT committee_NN members_NNS [_NN 8_CD ]_NN ._. In_IN comparison_NN to_TO those_DT in_IN other_JJ clinical_JJ
        departments_NNS ,_, surgical_JJ grant_NN proposals_NNS are_VBP less_RBR likely_JJ to_TO be_VB funded_VBN ,_, and_CC awards_NNS ,_, when_WRB
        funded_VBN ,_, are_VBP smaller_JJR [_NN 8_CD ]_NN ._.
        
          
            Funding_NNP agencies_NNS need_VBP to_TO recognize_VB the_DT importance_NN of_IN the_DT surgical_JJ endeavor_NN to_TO modern_JJ
            medicine_NN ._.
          
        
        Surgical_NNP research_NN is_VBZ also_RB impeded_VBN by_IN processes_VBZ affecting_VBG other_JJ types_NNS of_IN research_NN as_RB
        well_RB ._. The_DT number_NN of_IN researchers_NNS under_IN 35_CD years_NNS of_IN age_NN receiving_VBG a_DT first_JJ RO_NNP 1_CD grant_VB ,_, the_DT main_JJ
        NIH_NNP mechanism_NN for_IN external_JJ funding_NN ,_, in_IN any_DT field_NN ,_, is_VBZ below_IN 4_CD %_NN ._. The_DT average_JJ age_NN of_IN initial_JJ
        funding_NN for_IN US_NNP physicians_NNS is_VBZ about_IN 44_CD years_NNS ,_, and_CC shows_VBZ a_DT trend_NN toward_IN advancing_VBG age_NN that_WDT
        has_VBZ progressed_VBN significantly_RB in_IN the_DT past_JJ two_CD decades_NNS ._. Thus_RB ,_, the_DT NIH_NNP appears_VBZ to_TO reward_VB
        experience_NN and_CC proven_VBN results_NNS very_RB heavily_RB ,_, which_WDT may_MD stifle_VB innovation_NN and_CC likely_JJ serves_VBZ
        as_IN an_DT innate_JJ barrier_NN for_IN younger_JJR physician-investigators_JJ contemplating_VBG research_NN careers_NNS
        [_NN 9_CD ]_NN ._.
        To_TO help_VB correct_JJ for_IN this_DT worrisome_JJ trend_NN ,_, the_DT NIH_NNP created_VBD the_DT “ K_NNP” award_NN system—career_NN
        development_NN grants_NNS designed_VBN to_TO help_VB starting_VBG researchers_NNS gain_VBP the_DT experience_NN needed_VBN to_TO
        compete_VB for_IN RO_NNP 1_CD grants_NNS ._. However_RB ,_, nearly_RB 40_CD %_NN of_IN the_DT clinicians_NNS who_WP receive_VBP KO_NNP 8_CD awards_NNS never_RB
        apply_VBP for_IN RO_NNP 1_CD funding_NN [_NN 10_CD ]_NN ,_, which_WDT suggests_VBZ that_IN the_DT overall_JJ support—both_NN explicit_JJ and_CC
        implicit—for_NN clinical_JJ research_NN at_IN the_DT institutional_JJ and_CC funding_NN levels_NNS is_VBZ inadequate_JJ ._.
        Finally_RB ,_, outside_IN the_DT US_NNP ,_, surgeons_NNS face_VBP similar_JJ ,_, if_IN not_RB greater_JJR problems_NNS ._. This_DT bodes_VBZ
        poorly_RB for_IN countries_NNS where_WRB the_DT cost_NN of_IN evaluating_VBG new_JJ therapies_NNS and_CC technologies_NNS may_MD be_VB an_DT
        unaffordable_JJ luxury_NN ._. These_DT challenges_NNS to_TO the_DT surgical_JJ research_NN enterprise_NN are_VBP therefore_RB
        global_JJ issues_NNS and_CC should_MD merit_VB the_DT attention_NN of_IN surgeons_NNS ,_, medical_JJ institutions_NNS ,_, and_CC funding_NN
        agencies_NNS in_IN all_DT countries_NNS ._.
      
      
        The_DT Future_NNP
        What_WP can_MD be_VB done_VBN ?_. On_IN the_DT national_JJ and_CC international_JJ level_NN ,_, funding_NN agencies_NNS need_VBP to_TO
        recognize_VB the_DT importance_NN of_IN the_DT surgical_JJ endeavor_NN to_TO modern_JJ medicine_NN ._. Recently_RB ,_, in_IN the_DT US_NNP
        the_DT NIH_NNP unveiled_VBD a_DT “ roadmap_NN” (_( http_NN :_: /_NN /_NN nihroadmap_NN ._. nih_NN ._. gov_NN )_) designed_VBN to_TO provide_VB “ new_JJ pathways_NNS
        to_TO discovery_NN ._.” Clear_NNP ,_, careful_JJ ,_, scientific_JJ surgical_JJ investigation_NN must_MD be_VB part_NN of_IN this_DT
        roadmap_NN ,_, although_IN it_PRP is_VBZ not_RB specifically_RB mentioned_VBN ._. Outreach_NNP efforts_NNS to_TO include_VB surgeons_NNS in_IN
        a_DT variety_NN of_IN study_NN sections_NNS should_MD be_VB made_VBN to_TO ensure_VB that_IN important_JJ insights_NNS into_IN the_DT
        pathophysiology_NN and_CC treatment_NN of_IN disease_NN ,_, with_IN which_WDT surgeons_NNS are_VBP concerned_VBN on_IN a_DT daily_JJ
        basis_NN ,_, are_VBP not_RB overlooked_VBN ._. Additional_JJ efforts_NNS are_VBP needed_VBN to_TO improve_VB funding_NN for_IN clinical_JJ
        research_NN ,_, both_DT for_IN individuals_NNS at_IN early_JJ stages_NNS of_IN their_PRP$ careers_NNS and_CC for_IN multi-disciplinary_JJ
        clinical_JJ research_NN and_CC clinical_JJ trials_NNS ._. Locally_RB ,_, and_CC individually_RB ,_, surgeons_NNS must_MD join_VB
        efforts_NNS to_TO improve_VB the_DT clinical_JJ research_NN enterprise_NN by_IN including_VBG training_NN in_IN clinical_JJ
        investigation_NN at_IN an_DT early_JJ stage_NN in_IN medical_JJ school_NN and_CC during_IN surgical_JJ residency_NN training_NN ,_,
        fostering_VBG the_DT careers_NNS of_IN young_JJ surgeon-investigators_JJ through_IN committed_VBN ,_, protected_VBN time_NN ,_,
        participating_VBG in_IN local_JJ and_CC national_JJ clinical_JJ research_NN groups_NNS ,_, and_CC recognizing_VBG that_DT
        development_NN as_IN a_DT clinical_JJ researcher_NN takes_VBZ time—many_NN years_NNS in_IN fact_NN ._.
        These_DT efforts_NNS may_MD help_VB ensure_VB that_IN surgical_JJ research_NN is_VBZ a_DT vital_JJ part_NN of_IN the_DT future_NN of_IN
        medicine_NN and_CC that_IN it_PRP leads_VBZ to_TO the_DT kind_NN of_IN high-quality_JJ work_NN that_WDT shapes_VBZ and_CC remodels_NNS the_DT
        face_NN of_IN medicine_NN ._. To_TO foster_VB these_DT efforts_NNS ,_, surgeons_NNS must_MD change_VB and_CC adapt_VB to_TO the_DT currents_NNS
        of_IN modern_JJ medical_JJ research_NN ._. If_IN this_DT is_VBZ successful_JJ ,_, the_DT case_NN series_NN will_MD become_VB the_DT
        occasional_JJ rather_RB than_IN the_DT common_JJ form_NN of_IN surgical_JJ communication_NN ._. And_CC surgeons_NNS ,_, other_JJ
        clinicians_NNS ,_, and_CC ,_, most_RBS importantly_RB ,_, basic_JJ scientists_NNS will_MD be_VB better_RBR able_JJ to_TO take_VB advantage_NN
        of_IN the_DT new_JJ avenues_NNS of_IN biomedical_JJ science_NN opening_NN before_IN us_PRP ._.
        But_CC the_DT case_NN series_NN will_MD always_RB represent_VB one_CD important_JJ tool_NN for_IN early_JJ studies_NNS or_CC
        uncommon_JJ conditions_NNS ._. It_PRP remains_VBZ true_JJ that_IN while_IN the_DT method_NN one_CD uses_VBZ influences_VBZ the_DT answer_NN
        one_CD receives_VBZ ,_, it_PRP can_MD be_VB just_RB as_IN important_JJ to_TO ask_VB the_DT right_JJ questions_NNS ,_, which_WDT can_MD be_VB asked_VBN
        even_RB in_IN a_DT series_NN of_IN one_CD patient_NN [_NN 11_CD ]_NN ._. And_CC surely_RB that_WDT is_VBZ the_DT place_NN one_PRP must_MD begin_VB ._.
      
    
  
